TREVI THERAPEUTICS INC

TRVI is the ticker for Trevi Therapeutics, a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for patients with serious neurological and inflammatory conditions. Its lead investigational product is Haduvio (nalbuphine ER), which is being studied for chronic cough and other conditions. As a clinical-stage company, its progress depends heavily on clinical trial outcomes and regulatory decisions.

TRVI's recent performance is displayed in the price chart and performance data on this page, including daily, weekly, and year-to-date moves. Because the stock is tied to clinical-stage biotech developments, price action can be sensitive to trial updates and sector sentiment. For the latest performance figures, refer to the live data on this page.

Since TRVI is a clinical-stage biotech with no approved products generating revenue, traditional metrics like P/E ratios are often not meaningful. Investors may look at cash position, burn rate, enterprise value, and pipeline potential instead. Market cap relative to cash and future revenue prospects can also provide context. For specific valuation data, check the financial metrics shown on this page.

TRVI may be available for trading in pre-market and after-hours sessions through certain brokers, though liquidity is typically lower and spreads can be wider than during regular market hours. Extended-hours trading involves additional risks, including reduced volume and higher volatility. Check with your brokerage for specific availability and any associated fees or restrictions.

For TRVI, key financial metrics include cash and cash equivalents, operating expenses, research and development spending, and net loss. These help assess how long the company can fund its clinical programs. Investors may also monitor changes in liabilities and share count. Detailed financial statements and metrics are available on this page for further review.

TRVI faces risks common to clinical-stage biopharmaceutical companies, including the possibility that its drug candidates fail in clinical trials or do not receive regulatory approval. It may also face financing risk if it needs to raise additional capital, as well as competition and intellectual property challenges. These factors can significantly impact the stock price.